JP2023532293A - 抗ｎｍｅ抗体および癌または癌転移の治療方法 - Google Patents

抗ｎｍｅ抗体および癌または癌転移の治療方法 Download PDF

Info

Publication number
JP2023532293A
JP2023532293A JP2022580312A JP2022580312A JP2023532293A JP 2023532293 A JP2023532293 A JP 2023532293A JP 2022580312 A JP2022580312 A JP 2022580312A JP 2022580312 A JP2022580312 A JP 2022580312A JP 2023532293 A JP2023532293 A JP 2023532293A
Authority
JP
Japan
Prior art keywords
nme7
antibody
seq
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580312A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021263227A5 (https=
JP2023532293A5 (https=
Inventor
バムダッド，シンシア
スマッジ，ブノワ
Original Assignee
ミネルバ バイオテクノロジーズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/036500 external-priority patent/WO2021252551A2/en
Application filed by ミネルバ バイオテクノロジーズ コーポレーション filed Critical ミネルバ バイオテクノロジーズ コーポレーション
Publication of JP2023532293A publication Critical patent/JP2023532293A/ja
Publication of JPWO2021263227A5 publication Critical patent/JPWO2021263227A5/ja
Publication of JP2023532293A5 publication Critical patent/JP2023532293A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
JP2022580312A 2020-06-26 2021-06-27 抗ｎｍｅ抗体および癌または癌転移の治療方法 Pending JP2023532293A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063044670P 2020-06-26 2020-06-26
US63/044,670 2020-06-26
US202063046852P 2020-07-01 2020-07-01
US63/046,852 2020-07-01
PCT/US2021/036500 WO2021252551A2 (en) 2020-06-08 2021-06-08 Anti-nme antibody and method of treating cancer or cancer metastasis
USPCT/US2021/036500 2021-06-08
PCT/US2021/039291 WO2021263227A2 (en) 2020-06-26 2021-06-27 Anti-nme antibody and method of treating cancer or cancer metastasis

Publications (3)

Publication Number Publication Date
JP2023532293A true JP2023532293A (ja) 2023-07-27
JPWO2021263227A5 JPWO2021263227A5 (https=) 2024-06-28
JP2023532293A5 JP2023532293A5 (https=) 2024-06-28

Family

ID=79281989

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580312A Pending JP2023532293A (ja) 2020-06-26 2021-06-27 抗ｎｍｅ抗体および癌または癌転移の治療方法

Country Status (9)

Country Link
US (2) US20230242678A1 (https=)
EP (1) EP4172215A4 (https=)
JP (1) JP2023532293A (https=)
KR (1) KR20230028796A (https=)
CN (1) CN116075318A (https=)
AU (1) AU2021297535A1 (https=)
CA (1) CA3183682A1 (https=)
IL (1) IL299332A (https=)
WO (1) WO2021263227A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106414726A (zh) 2014-04-07 2017-02-15 米纳瓦生物技术公司 抗nme抗体
EP3920693A4 (en) 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
CN116367857A (zh) 2020-06-08 2023-06-30 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
KR20230028796A (ko) * 2020-06-26 2023-03-02 미네르바 바이오테크놀로지 코포레이션 항-nme 항체 및 암 또는 암 전이의 치료 방법
KR20250009592A (ko) 2022-04-12 2025-01-17 미네르바 바이오테크놀로지 코포레이션 항-가변 muc1* 항체 및 그의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514099A (ja) * 2013-02-20 2016-05-19 ミネルバ バイオテクノロジーズ コーポレーション Ｎｍｅ阻害剤、及びｎｍｅ阻害剤を使用する方法
US20160326263A1 (en) * 2013-02-20 2016-11-10 Minerva Biotechnologies Corporation NME Inhibitors and Methods of Using NME Inhibitors
JP2017512825A (ja) * 2014-04-07 2017-05-25 ミネルバ バイオテクノロジーズ コーポレーション 抗ｎｍｅ抗体

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5631271A (en) 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
US5874285A (en) 1996-09-13 1999-02-23 Incyte Pharmaceuticals, Inc. Polynucleotide encoding a novel human nm23-like protein
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
JP2002535656A (ja) 1999-01-23 2002-10-22 ミナーヴァ・バイオテクノロジーズ・コーポレーション コロイド固定化種と非コロイド構造上の種との相互作用
JP5122705B2 (ja) 1999-01-25 2013-01-16 ミナーヴァ・バイオテクノロジーズ・コーポレーション 神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出
WO2002001230A2 (en) 2000-06-23 2002-01-03 Minerva Biotechnologies Corporation Rapid and sensitive detection of protein aggregation
CA2384713A1 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
JP2003535099A (ja) 2000-05-26 2003-11-25 ミナーヴァ・バイオテクノロジーズ・コーポレーション 化学又は生物学的事象を検出するための信号変換器としてのメタロセン
AU7014001A (en) 2000-06-23 2002-01-08 Minerva Biotechnologies Corp Interaction of colloid-immobilized species with species on non-colloidal structures
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
WO2002029411A2 (en) 2000-10-03 2002-04-11 Minerva Biotechnologies Corporation Magnetic in situ dilution
JP4335526B2 (ja) 2000-11-01 2009-09-30 ミナーヴァ・バイオテクノロジーズ・コーポレーション コロイド構造体および非コロイド構造体による結合スピーシーズの検出
EP1348034B1 (en) 2000-11-15 2016-07-20 Minerva Biotechnologies Corporation Oligonucleotide identifiers
EP2322929B1 (en) 2000-11-27 2016-04-06 Minerva Biotechnologies Corporation diagnostics, drug screening and treatment for cancer
WO2003018846A1 (en) 2001-08-31 2003-03-06 Minerva Biotechnologies Corporation Affinity tag modified particles
EP1434584A2 (en) 2001-09-05 2004-07-07 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
JP2005507876A (ja) 2001-09-05 2005-03-24 ミナーバ バイオテクノロジーズ コーポレイション 癌を治療する組成物および方法
US20050163784A1 (en) 2002-06-17 2005-07-28 Valentijn Linda J. Novel cancer therapies
CA2491017A1 (en) 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
CA2537263C (en) 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
WO2004050860A2 (en) 2002-12-04 2004-06-17 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
JP2006517674A (ja) 2002-12-20 2006-07-27 ミネルバ バイオテクノロジーズ コーポレーション ナノ粒子を含む光学デバイスおよび方法
US20080064680A1 (en) 2004-09-14 2008-03-13 Bamdad Cynthia C Methods for Diagnosis and Treatment of Cancer
DK1875244T3 (en) 2005-03-30 2019-04-29 Minerva Biotechnologies Corp Proliferation of MUC1-Expressing Cells
CA2610292C (en) 2005-03-30 2015-06-02 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
CA2611728A1 (en) 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
WO2007072221A2 (en) 2005-11-10 2007-06-28 Aurelium Biopharma Inc. Surface marker-directed cancer therapeutics
CN101652469B (zh) 2006-12-06 2014-04-16 米纳瓦生物技术公司 用于鉴定和操作细胞的方法
US20100254996A1 (en) 2007-06-18 2010-10-07 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
WO2009042815A1 (en) 2007-09-25 2009-04-02 Minerva Biotechnologies Corp. Methods for treatment of cancer
WO2009042814A1 (en) 2007-09-25 2009-04-02 Minerva Biotechnologies Corp. Early diagnosis and treatment of drug resistance in muc1-positive cancer
US11202775B2 (en) 2007-09-25 2021-12-21 Minerva Biotechnologies Corporation Methods for treatment of cancer
DK2334703T3 (en) * 2008-09-17 2015-10-05 Innate Pharma Configurations and methods for detection of tlr3
US20170204191A1 (en) 2008-10-06 2017-07-20 Cynthia C. Bamdad Muc1* antibodies
US20110195089A1 (en) 2008-10-08 2011-08-11 The Adminstrators Of The Tulane Educational Fund Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
WO2010042891A2 (en) 2008-10-09 2010-04-15 Minerva Biotechnologies Corporation Method for inducing pluripotency in cells
US20100179213A1 (en) 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
SG176801A1 (en) 2009-06-11 2012-01-30 Minerva Biotechnologies Corp Methods for culturing stem and progenitor cells
EP3228629A1 (en) 2010-06-16 2017-10-11 Minerva Biotechnologies Corporation Reprogramming cancer cells
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2686418A4 (en) 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
EP2707021B1 (en) 2011-05-09 2024-02-21 Minerva Biotechnologies Corporation Genetically engineered growth factor variants
EP2768945B1 (en) 2011-10-17 2022-01-05 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
US20240247229A1 (en) 2011-10-17 2024-07-25 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
WO2013123084A1 (en) 2012-02-13 2013-08-22 Minerva Biotechnologies Corporation Method for detecting circulating fetal cells
CA2864872C (en) 2012-02-24 2022-07-05 Alteogen Inc. Modified antibody in which motif comprising cysteine residue is bound
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
JP6748430B2 (ja) 2012-07-13 2020-09-02 ミネルバ バイオテクノロジーズ コーポレーション より未分化状態への細胞の誘導方法
CN111849874A (zh) 2012-07-24 2020-10-30 米纳瓦生物技术公司 Nme变体物种表达和抑制
CN104717980A (zh) 2012-08-14 2015-06-17 米纳瓦生物技术公司 干细胞增强疗法
CA2886161A1 (en) * 2012-09-29 2014-04-03 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
TWI659210B (zh) 2013-08-12 2019-05-11 Minerva Biotechnologies Corporation 加強腫瘤生長的方法
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
US20170106046A1 (en) 2015-03-03 2017-04-20 Minerva Biotechnologies Corporation Method for diagnosing and treating cancer using naive state stem cell specific genes
AU2016287603A1 (en) 2015-07-01 2018-01-25 Minerva Biotechnologies Corporation Method of stem cell-based organ and tissue generation
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP2019515643A (ja) 2015-09-23 2019-06-13 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞分化剤のスクリーニング方法
WO2018010140A1 (zh) 2016-07-14 2018-01-18 中国科学院生物物理研究所 I型干扰素受体抗体及其用途
WO2018054240A1 (en) 2016-09-20 2018-03-29 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pcsk9 antibodies
JP2020500031A (ja) * 2016-10-11 2020-01-09 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊抗体及び開裂酵素の使用
EP3600451B1 (en) 2017-03-29 2025-12-24 Minerva Biotechnologies Corporation Agents for differentiating stem cells and treating cancer
WO2019104306A1 (en) 2017-11-27 2019-05-31 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and direct use of cleavage enzyme
WO2019126357A1 (en) 2017-12-19 2019-06-27 Minerva Biotechnologies Corporation Agents for treating cancer and methods for identifying said agents
CN112272677B (zh) 2018-02-26 2024-10-29 米纳瓦生物技术公司 使用抗muc1＊抗体的诊断方法
US20200405832A1 (en) 2018-03-09 2020-12-31 Minerva Biotechnologies Corporation Method for anti-muc1* car t cell stimulation
JP2022527144A (ja) 2019-01-11 2022-05-31 ミネルヴァ バイオテクノロジーズ コーポレーション 抗可変ｍｕｃ１＊抗体およびその使用
EP3920693A4 (en) * 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
CN116367857A (zh) * 2020-06-08 2023-06-30 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
KR20230028796A (ko) 2020-06-26 2023-03-02 미네르바 바이오테크놀로지 코포레이션 항-nme 항체 및 암 또는 암 전이의 치료 방법
CA3183958A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Methods for deriving dopaminergic neurons from pluripotent stem cells
CN116234828A (zh) 2020-07-29 2023-06-06 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
KR20250009592A (ko) 2022-04-12 2025-01-17 미네르바 바이오테크놀로지 코포레이션 항-가변 muc1* 항체 및 그의 용도
EP4522206A1 (en) 2022-05-09 2025-03-19 Minerva Biotechnologies Corporation Chimeric antigen receptor and il-18 receptor compositions and methods of use therein
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514099A (ja) * 2013-02-20 2016-05-19 ミネルバ バイオテクノロジーズ コーポレーション Ｎｍｅ阻害剤、及びｎｍｅ阻害剤を使用する方法
US20160326263A1 (en) * 2013-02-20 2016-11-10 Minerva Biotechnologies Corporation NME Inhibitors and Methods of Using NME Inhibitors
JP2017512825A (ja) * 2014-04-07 2017-05-25 ミネルバ バイオテクノロジーズ コーポレーション 抗ｎｍｅ抗体

Also Published As

Publication number Publication date
EP4172215A2 (en) 2023-05-03
AU2021297535A1 (en) 2023-02-16
US12415868B1 (en) 2025-09-16
WO2021263227A2 (en) 2021-12-30
WO2021263227A3 (en) 2022-02-10
CN116075318A (zh) 2023-05-05
EP4172215A4 (en) 2024-11-20
IL299332A (en) 2023-02-01
US20230242678A1 (en) 2023-08-03
CA3183682A1 (en) 2021-12-30
KR20230028796A (ko) 2023-03-02

Similar Documents

Publication Publication Date Title
US12479928B2 (en) Anti-cancer peptide
US12037413B2 (en) Anti-NME antibody and method of treating cancer or cancer metastasis
US12415868B1 (en) Anti-NME antibody and method of treating cancer or cancer metastasis
US12049514B2 (en) Anti-NME antibody and method of treating cancer or cancer metastasis
JPWO2021263227A5 (https=)
JPWO2021252551A5 (https=)
AU2026202696A1 (en) Anti-NME antibody and method of treating cancer or cancer metastasis
HK40101426A (zh) 抗nme抗体及治疗癌症或癌症转移的方法
HK40094150A (zh) 抗nme抗体及治疗癌症或癌症转移的方法
HK40064429B (zh) 抗nme抗体及治疗癌症或癌症转移的方法
HK40064429A (en) Anti-nme antibody and method of treating cancer or cancer metastasis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260105